Diabetic Neuropathy R&D Services
Diabetic cataract is one of the most common ocular complications in individuals with diabetes. Its pathogenesis is complex and characterized by rapid progression and high risk of blindness. Ace Therapeutics integrates basic research, preclinical validation, and translational research capabilities to provide full-cycle R&D services from "mechanism analysis" to "preclinical development" for pharmaceutical companies, research institutes, and healthcare organizations. Our services are designed to help accelerate the R&D process of diabetic cataract diagnostic technologies, therapeutic drugs and intervention programs.
Our Diabetic Neuropathy R&D Services
Ace Therapeutics delivers end-to-end research services for diabetic neuropathy, leveraging integrated platforms in mechanism elucidation, preclinical modeling, and translational validation.
We focus on the pathomechanisms of diabetic cataracts and provide customized research support to guide targeted research and development.
- Analysis of metabolic disorder mechanisms: analyze the dynamic changes of characteristic metabolites (e.g., sorbitol, fructose, late glycosylation end-products AGEs) in lens, atrial fluid, and serum by metabolomics techniques (e.g., LC-MS/MS), and clarify the pathways of hyperglycemia's effect on lens metabolism.
- Oxidative stress and inflammation investigation: Quantifying reactive oxygen species (ROS) levels, antioxidant enzyme (SOD, GSH-Px) activities, and inflammatory cytokine (IL-6, TNF-α) expression in the lens to validate the role of oxidative-inflammatory pathways in disease progression.
- Crystallin protein damage investigation: Employing proteomic approaches to identify glycation and oxidative modification sites in α/β-crystallins, elucidating mechanistic links between protein aggregation and lens opacification.
We provide professional diabetic neuropathy modeling services dedicated to accelerating your drug discovery and mechanism research through highly predictive preclinical models that recapitulate human disease progression. Our services utilize well-established induction methods, such as streptozotocin-induced diabetes, to reliably develop diabetic models in rodents. We conduct comprehensive behavioral, electrophysiological, and molecular assessments to fully characterize key peripheral neuropathy phenotypes, including abnormal pain sensitivity, reduced nerve conduction velocity, and nerve fiber damage.
Ace Therapeutics leverages our proprietary expertise to advance the development and refinement of diabetic cataract therapeutics, including antioxidants, aldose reductase inhibitors, and anti-inflammatory agents.
- Drug candidate screening: Utilizing cellular models (glucose-stressed lens epithelial cells, LECs) and established animal models to evaluate therapeutic efficacy in ameliorating lens opacity, quantified through standardized opacity scoring and light transmittance assays.
- Pharmacodynamic mechanism validation: Assessing drug modulatory effects on metabolic pathways (e.g., sorbitol pathway), oxidative stress levels, and protein aggregation to definitively identify molecular targets.
We develop early and accurate diagnostic protocols for diabetic cataracts based on biomarkers and imaging techniques.
- Biomarker discovery and validation: Employing integrated multi-omics screening (metabolomics + proteomics) to identify diagnostic biomarkers with high specificity (e.g., α-B-crystallin fragments in aqueous humor, serum AGEs), and developing ELISA detection kits for clinical translation.
- Imaging diagnostics system development: Integrating high-resolution OCT and fundus cameras to create AI-assisted diagnostic algorithms that achieve quantitative grading of lens opacification, enabling early screening and progression monitoring.
- Translating minimally invasive testing technology: We develop minimally invasive tear and atrial fluid-based sample testing methods to meet the need for rapid screening.
Based on biomarker and imaging technologies, we help our clients develop early and accurate diagnostic programs for diabetic cataracts.
- Translating minimally invasive testing technology: Developing minimally invasive tear and atrial fluid-based sample testing methods to help clients meet rapid screening needs.
- Diagnostic imaging system development: Combining high-resolution OCT and fundus camera, develop AI-assisted diagnostic algorithms to quantitatively grade the degree of lens clouding and support early screening and progress monitoring.
Advantages of Our Diabetic Neuropathy R&D Services
- Leading-edge technology platform: We have a comprehensive technology platform equipped with state-of-the-art equipment such as ultra-high resolution mass spectrometry (QE-HF), fundus OCT, etc., which can provide stable and reliable data.
- Mature model system: We provide reliable diabetic retinopathy models, including animal models and cellular models, which can meet the demands of our clients at different stages of research and development.
- Customized service capability: We can provide customized service solutions according to clients' needs, including specific mechanism research, special model construction and personalized testing indicators.
Ace Therapeutics not only provides technical services, but also aims to be your long-term partner in diabetic cataract research and development to drive translational breakthroughs from scientific discovery to preclinical benefit. Please contact us for more details and we will provide you with customized solutions.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
